Company: DHR
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0000313616-25-000088
Chunk: 11

Company: DANAHER CORP /DE/
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 1
Chunk 11
---
reciation(42)(38)(97)(2)(179)Amortization of intangible assets(218)(141)(48)— (407)Other segment expenses(b)(939)(1,331)(1,552)(76)(3,898)Operating profit$325 $235 $830 $(78)$1,312 (a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.(b) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses, research and development (“R&D”) expenses, excluding in each case depreciation and amortization of intangible assets.  Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses. The following table presents identifiable assets as of March 28, 2025 and December 31, 2024 ($ in millions):March 28, 2025December 31, 2024Identifiable assets:Biotechnology$36,121 $34,605 Life Sciences23,396 23,211 Diagnostics14,291 14,204 Other5,308 5,522 Total$79,116 $77,542 The following table presents capital expenditures for the three-month periods ended March 28, 2025 and March 29, 2024 ($ in millions):Three-Month Period EndedMarch 28, 2025March 29, 2024Capital expenditures:Biotechnology$81 $102 Life Sciences48 60 Diagnostics115 127 Other1 2 Total$245 $291 

10

NOTE 6.  INCOME TAXES

The following table summarizes the Company’s effective tax rate:Three-Month Period EndedMarch 28, 2025March 29, 2024Effective tax rate15.5 %14.4 %The Company operates globally, including in certain jurisdictions with lower tax rates than the United States (“U.S.”) federal statutory rate.  Therefore, the impact of Danaher’s global operations and benefits from tax credits and incentives contributes to a lower effective tax rate compared to the U.S. federal statutory tax rate.  For each period presented, the effective tax rate differs from the U.S. federal statutory rate of 21.0% principally due to the impact of the Company’s global operations, research tax credits, foreign-derived intangible